58 results about "Pulmonary emphysema" patented technology

The embodiment of the invention provides an emphysema CT image segmentation method based on multi-feature dynamic fusion and boundary perception, and is applied to the field of medical lung CT image segmentation, the method obtains an original image by obtaining an emphysema CT image and preprocessing the emphysema CT image, and the preprocessing comprises extraction and standardization of a lung parenchyma region of interest; inputting the original image into the trained emphysema CT image segmentation model for segmentation to obtain an image segmentation result; wherein the emphysema CT image segmentation model comprises an encoder and a decoder, the encoder comprises a convolutional neural network branch, a Transform branch and a dynamic fusion module, the convolutional neural network branch is parallel to the Transform branch, and the decoder comprises an up-sampling layer and a boundary sensing module. The method improves the accuracy and reliability of the image segmentation result of the emphysema CT image.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a nauclea officinalis extract in preparation of a medicine for treating chronic obstructive pulmonary diseases. Experimental research shows that the nauclea officinalis extract is used for treating the chronic obstructive pulmonary disease, can inhibit lung inflammation of a patient suffering from the chronic obstructive pulmonary disease and improve the lung function and emphysema injury of the chronic obstructive pulmonary disease, can be used for preventing and treating the chronic obstructive pulmonary disease, and can be used for preventing and treating the chronic obstructive pulmonary disease. And a new strategy is provided for the development of medicines for treating chronic obstructive pulmonary diseases.

The present technology can be used to selectively heat one or more diseased regions in the lung while limiting heating of healthy regions and surrounding tissue. This heating provides a therapeutic effect. Selective heating of diseased tissue can be achieved by exposing the lung to an electromagnetic field to cause dielectric or eddy current heating. The present technology is particularly useful for treating emphysema because the diseased regions of emphysema patients have reduced blood flow. The diseased regions will heat up quickly while healthy tissue will be cooled by blood flow. This is particularly effective for treating emphysema because the lung has a small mass and high blood flow. In one described embodiment, the frequency of the electromagnetic radiation is chosen to satisfy certain resonance conditions of the device. In another described embodiment, a coil is used to apply the electromagnetic radiation, the geometric parameters of the coil being chosen so that an electric field maximum is produced in the region to be heated. In another described embodiment, a pair of electromagnetic energy signal applicators are used to apply the electromagnetic radiation, the pair of electromagnetic energy signal applicators being positioned to surround the torso of the patient, one electromagnetic energy signal applicator being positioned cephalad relative to the treatment region and the other electromagnetic energy signal applicator being positioned caudal relative to the treatment region, and the pair of electromagnetic energy signal applicators being shaped to encircle or partially encircle the periphery of the torso.

The present invention discloses a traditional Chinese medicine composition for treating chronic bronchitis combined with emphysema. The composition is prepared by extracting the following traditional Chinese medicine raw materials in parts by weight: 20-30 parts of ginseng, 15-25 parts of astragalus, 20-30 parts of prepared rehmannia, 18-22 parts of schisandra, 15-25 parts of pinellia, and 20-30 parts of poria. The composition nourishes the liver, spleen, and kidneys, reduces stomach qi, purges the lungs, and relieves asthma, promotes diuresis and reduces swelling, promotes blood circulation and removes blood stasis, regulates qi and resolves phlegm, and is suitable for treating chronic bronchitis combined with emphysema. The present invention also discloses a preparation method and use thereof.

The invention relates to the technical field of biological medicines, in particular to application of a CD20 inhibitor in treatment of chronic obstructive pulmonary diseases. The CD20 inhibitor can remarkably improve emphysema and small airway collagen deposition in chronic obstructive pulmonary diseases, inhibit expression of inflammatory factors IL-6 and TNF-alpha in lung tissue, reduce the concentration of chemotactic factors CXCL2 in bronchoalveolar lavage fluid and relieve lung inflammation, and the treatment effect is remarkable. Obviously, CD20 can become a potential clinical treatment target of chronic obstructive pulmonary disease.

The invention relates to the technical field of medical image processing, and discloses a chronic obstructive pulmonary emphysema distribution quantitative method and system based on multi-scale segmentation, and the method comprises the steps: carrying out the anisotropic diffusion filtering noise reduction of a chest CT image; segmenting a lung field and removing a blood vessel bronchial structure by adopting a region growing algorithm; multi-scale image representation is constructed based on a Gaussian pyramid, an emphysema candidate area is identified in a coarse scale layer, and a boundary is accurately drawn by adopting a self-adaptive threshold value in a fine scale layer; extracting local texture features to distinguish the lobular central emphysema and the total lobular emphysema; dividing severity levels according to spatial aggregation characteristics and density gradient distribution, and calculating an air swelling volume ratio and a distribution heterogeneity index; the three-dimensional pseudo-color volume is used for drawing visualization, a structured quantitative report is generated, accurate segmentation and subtype classification of the emphysema area are achieved, and comprehensive quantitative analysis indexes are provided.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

The application provides a method for constructing a mouse emphysema model and application, and the method comprises specifically knocking out a PHLDA1 gene in type II alveolar epithelial cells in lung tissue of an animal. Compared with a traditional method for establishing an animal mouse emphysema model by exposing to cigarette smoke, the mouse emphysema model has good stability, can be bred, has a short modeling cycle, and better simulates the lung tissue pathological changes and pathophysiological changes of emphysema patients, and has high consistency with the patients.

1. The name of the design product: lung instrument. 2. The use of the design product: for the auxiliary treatment of chronic bronchitis, chronic obstructive emphysema, bronchial asthma, and chronic pulmonary heart disease and other diseases. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention discloses a lung abnormal region detection method, device and equipment based on an attention mechanism. The method comprises the following steps: acquiring a lung image to be detected; the trained GLA-YOLO network is adopted to detect a lung abnormal region in the lung image to be detected, and a detection result of the lung image to be detected is obtained; the detection result comprises whether lung abnormal areas exist or not and the abnormal category of each lung abnormal area; wherein the GLA-YOLO network is a network obtained by improving the network structure of a YOLOV8 network, and a channel attention module, a space attention module and a C3E module based on a self-attention mechanism are fused in the GLA-YOLO network. According to the method, the detection precision of the lung abnormal region related to emphysema in the lung image can be remarkably improved.

The present invention relates to a novel method of treating pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency (AATD), a genetic disorder that causes low levels of alpha-1 antitrypsin (AAT), a protein that protects the lungs from damage by neutrophil elastase. The invention consists of aerosolizing nanoparticles composed of apolipoprotein A1 enriched with AAT (A1NP). The invention aims to deliver these nanoparticles directly to the lungs, where they can interact with the alveolar surface and modulate the inflammatory and proteolytic processes that lead to emphysema. In particular, the inventors report that said nanoparticles are not cytotoxic, have anti-inflammatory and anti-elastase properties, can cross alveolar epithelial cells, and are not immunogenic in mice.

A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C—S—C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine composition for treating chronic obstructive pneumonia and a pharmaceutical preparation. The traditional Chinese medicine composition comprises blackberry lily, honey-fried ephedra, dried ginger, asarum, honey-fried aster, honey-fried tussilago farfara, exocarpium citri rubrum, schisandra chinensis, fried semen raphani, perillaseed, semen brassicae and liquorice. The traditional Chinese medicine composition and the pharmaceutical preparation provided by the invention are used for patients with chronic obstructive pneumonia, can recover the pulmonary ventilation function, effectively inhibit inflammatory response in the body and promote lung tissue injury repair, and have a relatively good treatment effect on chronic obstructive pneumonia.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a pharmaceutical composition for treating hormone-resistant severe asthma and application of the pharmaceutical composition. The invention relates to an application of pentagalloylglucose (PGG) in preparation of a medicine for treating or preventing hormone-resistant severe asthma. The traditional Chinese medicine composition has a better effect on emphysema caused by severe asthma. The invention reveals and verifies that intestinal injury is a key upstream factor causing severe asthma and hormone resistance for the first time. Through targeted repair of intestinal tracts, the PGG can fundamentally remodel the immune microenvironment of the lung, and creates conditions for hormone to play a role. The discovery breaks through the limitation that traditional asthma treatment only focuses on local targets of the respiratory tract, and a brand new theoretical basis and a feasible solution are provided for overcoming the worldwide problem of hormone resistance.

The invention provides a method for constructing an emphysema mouse airway candida colonization model, and belongs to the technical field of candida colonization models.The method comprises the following steps that 1, an emphysema mouse model is constructed, including tobacco smoke exposure and elastase titration; and 2, establishing the pulmonary emphysema mouse Candida albicans airway colonization model, including preparation of a Candida albicans suspension and airway Candida colonization. The genomes of mice are closer to those of human beings than those of other animals, the mice have relatively wide gene, protein sequence and antibody availability, and the modeling cost of the mice is low, so that the mice are more suitable for experimental research of emphysema. Therefore, the construction method of the model is closer to a natural generation mode, is simple and convenient, can better simulate disease characteristics of candida albicans airway colonization in COPD, and creates conditions for further researching whether candida albicans airway colonization has a certain relationship with occurrence and development of COPD and acute exacerbation thereof.

The invention discloses application of a reagent for detecting LSH in preparation of a chronic obstructive pulmonary disease diagnosis preparation and application of a reagent for overexpressing the LSH in preparation of a medicine for treating the chronic obstructive pulmonary disease. Protein expression of LSH in a patient suffering from the chronic obstructive pulmonary disease is found to be lower than that of healthy people and expression of pure smokers through western blot and RT-qPCR detection for the first time. Therefore, the possibility of using the LSH as the detection marker of the chronic obstructive pulmonary disease is provided. The LSH overexpression adeno-associated virus improves obstructive ventilation dysfunction and large and small airway dysfunction of a model mouse, relieves the emphysema degree, reduces the airway inflammation level and inhibits small airway remodeling, and further analysis on inflammatory cells in the lung shows that the overexpression of the LSH overexpression adeno-associated virus can reduce the proportion of pulmonary interstitial macrophages. The invention provides a new way with a prospect for treating the chronic obstructive pulmonary disease.

Disclosed herein are methods of decreasing mucus hypersecretion in the lungs comprising administering an effective amount of a MUC1 inhibitor to a subject in need thereof. In certain embodiments, the MUC1 inhibitor is the peptide GO-201, GO-203, or GO-203-2C. In certain embodiments, the subject is a human patient. In certain embodiments, the subject is diagnosed with rhinosinusitis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, or a respiratory syncytial virus (RSV) infection.

The present application relates to a system for improving airflow within the bronchial tree of an emphysematous lung. The system comprises: a delivery device; and an implantable object comprising a distal end and a proximal end. The implantable object is configured to: place the implantable object through multiple generations of connected airways using the delivery device such that the distal end is placed in a first airway within a terminal portion of the bronchial tree and the proximal end is placed in a second airway within a mid-portion of the bronchial tree; and, when placing the implantable object through the multiple generations of connected airways, expand the implantable object such that at least a portion of the multiple generations of connected airways expands from (i) an initial diameter prior to placement of the implantable object to (ii) an expanded diameter that is greater than the initial diameter.

The invention relates to the technical field of biomedicine, in particular to application of CD19 serving as a chronic obstructive pulmonary disease diagnosis marker and a chronic obstructive pulmonary disease treatment target. The invention finds that the expression quantity of CD19 in the chronic obstructive pulmonary disease is increased and is in negative correlation with lung function indexes (FEV1 / FVC, FEV1% predicted); the number of CD19 positive cells in the lung of the patient with chronic obstructive pulmonary disease is increased for the first time; and it is found for the first time that the anti-CD19 antibody can relieve mouse emphysema and small airway collagen deposition caused by cigarette smoke exposure.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

This invention relates to the application of mitochondrial formulations in the preparation of drugs for treating chronic obstructive pulmonary disease (COPD). The mitochondrial formulations contain active mitochondria isolated from healthy donor cells, with a particle size of 400–1000 nm, possessing normal mitochondrial membrane potential and ATP generation function, and capable of being internalized by mammalian COPD lung epithelial cells. In vitro cell experiments have confirmed that this mitochondrial formulation can repair CSE-induced mitochondrial dysfunction in lung epithelial cells, inhibit mPTP opening, reduce mtDNA leakage into the cytoplasm, thereby blocking the activation of the cGAS-STING signaling pathway and reducing the release of inflammatory factors such as IL-1β and TNF-α. In vivo experiments in COPD mouse models show that tail vein injection of the mitochondrial formulation can effectively accumulate in lung tissue, significantly improving lung pathological changes such as emphysema and collagen fiber deposition in model mice. This invention provides a novel strategy for COPD treatment based on repairing mitochondrial function and intervening in inflammatory signaling pathways.

An implantable artificial bronchus (IAB) is provided that is used for the treatment of chronic obstructive pulmonary diseases, such as pulmonary emphysema. The implantable artificial bronchus can be made with silicone or nitinol, and has a tapered cylindrical shape. Additional embodiments of this apparatus may be further associated with a one-way valve on the nozzle of the IAB.

The application provides an adjustable medical instrument device, relates to the technical field of lung volume reduction instrument, and comprises an elastic implant body, an adjusting wire is arranged in the elastic implant body, and the adjusting wire extends along a preset shape of the elastic implant body; a first end of the adjusting wire is fixed at a proximal end of the elastic implant body, and a second end opposite to the first end of the adjusting wire is fixed at a distal end of the elastic implant body; wherein, the adjusting wire is provided with a pre-tightening force, so that the elastic implant body is close from the distal end to the proximal end, and the compression force of the elastic implant body acting on a target emphysema position is adjusted. Through the lung volume reduction instrument provided by the application, the problem that the compression force of the lung volume reduction instrument on the market is fixed and limited, the preset shape is insufficient, the residual air of the target emphysema position is not completely discharged, and the volume reduction effect is poor is solved.

The invention provides an adjustable medical instrument device, and relates to the technical field of lung volume reduction instruments, the adjustable medical instrument device comprises an elastic implant, an adjusting wire is arranged in the elastic implant, and the adjusting wire extends along with the preset shape of the elastic implant; the first end of the adjusting wire is fixed at the near end of the elastic implant, and the second end, opposite to the first end, of the adjusting wire is fixed at the far end of the elastic implant; wherein the adjusting wire applies a pre-tightening force, so that the elastic implant is close to the near end from the far end, and the compression force of the elastic implant acting on the target emphysema position is adjusted. According to the lung volume reduction instrument provided by the invention, the problems that the residual gas at the target emphysema position is not discharged thoroughly and the volume reduction effect is poor due to the fact that the compression force of the lung volume reduction instrument in the existing market is fixed and limited and the lung volume reduction instrument is not fully recovered to the preset shape are solved.

The application discloses application of a reagent for detecting LSH in preparation of a preparation for diagnosing chronic obstructive pulmonary disease and application of a reagent for overexpressing LSH in preparation of a medicine for treating chronic obstructive pulmonary disease. The application finds that the protein expression of LSH in a smoking chronic obstructive pulmonary disease patient is lower than that in a healthy person and a simple smoker for the first time through Western blotting and RT-qPCR detection. Therefore, the application provides a possibility for LSH as a detection marker for chronic obstructive pulmonary disease. The application improves the obstructive ventilation dysfunction of a model mouse and the function disorder of large and small airways, reduces the degree of pulmonary emphysema, reduces the airway inflammation level and inhibits small airway remodeling through LSH overexpression adeno-associated virus, and further analysis of inflammatory cells in the lung finds that the overexpression can reduce the proportion of pulmonary interstitial macrophages. The application provides a promising new way for the treatment of chronic obstructive pulmonary disease.

The present invention relates to a novel Lactobacillus fermentum HEM20792 strain, a composition comprising the strain or a culture thereof for preventing or treating chronic obstructive pulmonary disease (COPD), and the like. The composition comprising a Lactobacillus fermentum HEM20792 strain (KCTC14066BP) as an active ingredient, according to the present invention, inhibits lung tissue damage and suppresses immune cells, and thus can prevent or treat COPD including emphysema. Therefore, it is expected that the present invention can be used to help cure pulmonary disease by eliminating a fundamental cause of COPD.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

The present disclosure provides a newly-identified transitional cell state in alveolar regeneration, models to ablate lung alveolar type-1 cells that leads to lung fibrosis and emphysema, a scalable, an ex vivo lung fibrosis model that uses co-cultured lung fibroblasts and pre-alveolar type-1 transitional cell state (PATS) for the use of disease modeling and drug screening, and methods of using same.